Substituted pyridotriazine compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-12187734-B2
Application number	US-202318393778-A
Country	US
Kind code	B2
Filing date	Dec 22, 2023
Priority date	Jan 19, 2021
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

First claim

What is claimed:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

10. The compound of claim 1 wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

12. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is:

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or the pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or the pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or the pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or the pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises the compound:

or the pharmaceutically acceptable salt thereof.

21. A method of treating an HIV infection in a human having or at risk of having the infection, comprising administering to the human a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

22. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

23. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

24. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

25. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

26. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

27. The method of claim 21 , comprising administering to the human a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

Assignees

• Gilead Sciences Inc

Inventors

• Chu Hang
• Gonzalez Buenrostro Ana Z
• Guo Hongyan
• Han Xiaochun
• Hurtley Anna E
• Jiang Lan
• Li Jiayao
• Lin David W
• Mitchell Michael L
• Naduthambi Devan
• Schwarzwalder Gregg M
• Szewczyk Suzanne M
• Von Bargen Matthew J
• Wu Qiaoyin
• Yang Hong
• Zhang Jennifer R

Classifications

• C07D491/22

  in which the condensed system contains four or more hetero rings · CPC title

• C07D487/22

  in which the condensed system contains four or more hetero rings · CPC title

• A61P31/18

  for HIV · CPC title

• C07D471/22

  in which the condensed systems contains four or more hetero rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title